Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
will drop to 150.00 range with upcoming dilution. Shorts will be taking advantage .
The perfect Pair Trade short MDGL which is overbought and buy Viking which is trading 8X less in Value but has a better lipid drug and pipeline only 6 months behind madrigal's and hugely undervalued compared to MDGL.
If you look at history of offerings here recently the price action it will be turning upward once again. Matter of fact last time it was oversubscribed ..... CEO is not going to do a offer for 6.00 nor 7.00 . Have fun buying it/ shortcovering above 10.00 next week.
Price target 12.00 -15.00 in June
Shorts are getting destroyed. VK2809 enrollment is complete. Institutional buying is getting crazy...they are loading up !
It is impressive that management is fully invested with us. It gives me confidence.
They have 20 million in the bank already, I do not expect it anytime soon.
VKTX Should be trading at 72.00 if fairly compared to MDGL valuation.
VKTX: Positive Data from Madrigal is Positive for Viking; Raising Valuation to $16
https://finance.yahoo.com/news/vktx-positive-data-madrigal-positive-140000122.html
It trades/listed on Nasdaq , check your facts before posting.
Time for a short squeeze...shorts are trapped LOL
VKTX long
When this hits 10.00 , I'm flying to Vancouver B. C. to buy you a Beer for getting me in this stock. see you soon. Thank you Brother.
VKTX
VK2809 is a more effective and safer Lipid drug than MDGL's . When P2 results come in early Q4 you will see this stock correctly valued at 30.00 - 50.00 range. VKTX has a better pipeline than MDGL as well. VKTX is still extremely undervalued.
VKTX
Institutional buying today loading for Q4 ....Whales showing up in full force. Volume is crazy !
VKTX
The Longs here Knew this would happen.......congrats
VKTX
Volume is crazy !!!!! what a Monster !!!!!
VKTX
Skipper this stock is going Nuts , congrats to all the longs on here.
See you guys at 30.00 +++++ Q4
Go VKTX
SEATTLE — Nearly half of U.S. cancer doctors who responded to a survey say they’ve recently recommended medical marijuana to patients, although most say they don’t know enough about medicinal use.
The results reflect how marijuana policy in some states has outpaced research, the study authors said. All 29 states with medical marijuana programs allow doctors to recommend it to cancer patients. But no rigorous studies in cancer patients exist. That leaves doctors to make assumptions from other research on similar prescription drugs, or in other types of patients.
“The big takeaway is we need more research, plain and simple,” said Dr. Ilana Braun of Dana-Farber Cancer Institute in Boston, who led the study published Thursday in the Journal of Clinical Oncology.
Patients want to know what their doctors think about using marijuana. In the new study, cancer doctors said their conversations about marijuana were almost always started by patients and their families, not by the doctors themselves.
Overall, nearly eight in 10 cancer doctors reported having discussed marijuana with patients or their families, with 46 percent recommending it for pain and other cancer-related problems to at least one patient in the past year.
Among those who said they recommended marijuana, 56 percent said they did not have sufficient knowledge to do so.
“They’re not as close-minded as you might think, and they also feel they have a lot to learn,” Braun said.
The survey was conducted in a random sample of cancer doctors; researchers got completed surveys from 237 doctors, or 63 percent.
Marijuana is considered an illegal drug by federal officials and federal restrictions have limited research. Last year, the National Academies of Sciences, Engineering and Medicine concluded the lack of scientific information about marijuana poses a risk to public health.
There’s evidence marijuana can treat chronic pain in adults and medications similar to marijuana can ease nausea from chemotherapy.
In the study, 67 percent of cancer doctors said they view marijuana as a useful addition to standard pain therapies, with 75 percent saying it posed less risk of overdose than opioids. About half view marijuana as equal to, or more effective than, standard treatments for cancer-related nausea.
Marijuana isn’t harmless. The National Academies report said pot smoking may be linked to higher chances of traffic accidents, chronic bronchitis from long-term use and schizophrenia and other causes of psychosis, especially in the most frequent users.
Dr. Steven Pergam of Seattle Cancer Care Alliance answers questions about marijuana’s safety from his colleagues at the treatment center.
His responses depend on the patient. A dying patient with cancer that’s spread? “Whatever they want to do to make themselves comfortable,” said Pergam, who wasn’t involved in the new research. A patient with leukemia, however, should be warned of a theoretical possibility of a fungal infection tied to cannabis use.
“If we’re not comfortable having these discussions, patients will get information from other sources, and it’s not going to be as reliable,” he said.
https://www.denverpost.com/2018/05/10/medical-marijuana-for-cancer-survey/
Thanks for the reply, so then it looks like they might announce a upcoming Proof of concept trial on other Niche indications vk5211 has to offer after they get a partner and have the final P2 results.
The pullback today on markets selloff on Italy was overdone and has no bearing on VKTX future.....hopefully MDGL data should drive VKTX over 6.00 + this week. GLTA
It was my first question and he did give an explanation but cant remember in full detail. I wish I had recorded it. I think he mentioned why in the CC possibly ?
I'm sure next year when the stock is trading above 30.00 there will be plenty more excited shareholders. ...Hmmm 100k ? I would buy more commons and also warrants. Also would probably keep a little dry powder to trade around my core position.
VKTX Long
Hey Skipper, It was was not long lasted about 20 minutes ,first impression is this Management team is solid and on top of their A game. There was only 1 other shareholder besides myself attending , shoutout to " Dr. P" nice to have met you, he said he reads this board and ST.
They did a brief vote and then read shareholder count...then I asked a few questions as to why delay in Q1 12 week readout with 5211 and We should expect readout later and yes data will confirm the 24 weeks. Asked about if they were using Urinary stress indicator in Partnership negotiations and Brian said no. Mentioned if they are finding ways to improve patient recruitment and he said yes it is being addressed, and lastly I made a comment about MDGL 's valuation and why we are undervalued, said expects us to catch up in valuation in the future. also mentioned that patient enrolment is just about done with VK2809 and to expect a PR on that near term.
will give you an update when I get back from the meeting... Cup and handle chart, and we have MDGL news coming that will send VKTX higher .
http://stockcharts.com/h-sc/ui?s=VKTX
Hey Buddy, hope all is well with you, the board has been kind of quiet but i suspect it will get busy as summer progresses.
Any thoughts on CEO comments about urinary stress incontinence indication and the potent effects on levator ani muscle ? I am hoping that we partner with a Pharma that sees the potential in VK5211 besides just the hip fracture.
"Scott Henry
Just a couple of questions, first with regard to 5211. What are your thoughts on potential stress urinary incontinence indication?
Brian Lian
It’s an interesting question. We have obviously generated, I think very compelling data in the setting of hip fracture. We know that this mechanism has shown some benefit in the setting of stress urinary incontinence. And there is no trial ongoing with another SARM in that setting. We find it really interesting and compelling opportunity. But I think our plan now is to continue the dialogue that we have with potential partners and see where those lead -- those conversations lead. And we’ll also be monitoring the progress with the other SARM and see what those data look like. And I believe that will be expected by the end of the year.
I will say it on the levator ani muscle, which is the muscle that many considered to be important in that setting, VK5211 has shown very potent effects. And so we do think that if the mechanism is validated in this next trial result, it would be really interesting for 5211. But at this point, the near-term plan is to certainly continue discussions with partners."
I will ask about why they reneged on their end of Q1 statement and 24 weeks confirming of the 12 weeks results. Thanks for the question.
Shareholder meeting is at 8 AM on May 24th at their main Office http://www.vikingtherapeutics.com/contact/, I will be there. If any of you guys have any questions you would like me to ask Management just post it on here and I will ask them. I spoke with VP Mike Morneau and he said not many people showed up last time so i'm hoping some of you guys can attend.
OnRocket , I cant find shareholder meeting info on their website so I will call them. I live here in San Diego about 15 min away from their office and plan on going to the meeting.
When is the shareholder meeting this month ? can someone post a link ? I would like to attend but cant find the info but know i read it was this month somewhere.
VKTX long
Q1 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4171938-viking-therapeutics-vktx-ceo-brian-lian-q1-2018-results-earnings-call-transcript?page=3
Many uses for VK5211, interesting article thanks . Looks like the stock is breaking out of its slump. I think its going to go back to 7.00 by end of the month.
VKTX long
This selloff has been brutal and overdone...we need a nice green candle to re set the chart here.
VKTX coiled up and ready to spring back to 6.00 range.
When Vk2809 results come later this year Its going to go way beyond 18.00.... 30.00 + this year if VK2809 data is good. GLTA
When vk5211 data comes by end of this month we should be back over 7.00 + ...hold tight. GLTA
Looks like all that fear mongering on the RS was waste of time for you ? TRTC stock held up pretty solid today.
30th annual Roth Conference today. Click this link to register & you can listen to our CEO at 3:00PM.
http://www.wsw.com/webcast/roth32/register.aspx?conf=roth32&page=index&url=http%3A//www.wsw.com/webcast/roth32/
Waffles thank you for the reply, I agree about the support in the 5.00 range,Plenty of Institutions that loaded on the offering will not let it drop below that mark. The low volume is also letting the MM's fade it till we get some news which is close . Brian should release vk5211 data at conference today.
As for Vk2809 and the trials delayed I still wonder if MDGL had the same problem recruiting Patients with their lipid drug in P2 ? and since you mentioned they can pay the patients however much they want they should do it. Its crucial that they keep close to MDGL timeline with their drug now ready for P3.
There are a few Bone Franchises like Hoffman-LaRoche , GlaxoSmithKline with drug Boniva the prescription medication is used to treat osteoporosis and hypercalcemia. They could be a prime Partner for VK5211.
Keep up the great work here Waffles, stay well brother.
"Like VK2809, a competing drug MGL-3196 using the same mechanism of action has already achieved positive data in both NASH and hypercholesterolemia."
https://seekingalpha.com/article/4154375-viking-tumbles-phase-2-trial-delay-remains-solid-buy
VKTX Market cap 260 million...and MDGL has a 1.8 billion Market Cap.
VKTX Lipid drug is better than MDGL's , once vk2809 results are released and are expected to be good...VKTX should be trading around at least 30.00 ...that would be similar to MDGL 131.00 stock price / Market Cap.
not to mention that is all MDGL has only 1 drug ....VKTX has a much deeper and valuable Pipeline
http://www.vikingtherapeutics.com/pipeline/overview/
VKTX also has VK5211 Phase 3
and VK0214
and vk0612
VKTX is the most undervalued stock I have ever seen.... JMHO
Compare VKTX lipid drug vk2809 to MDGL's lipid and their stock valuation. ....get back to me and tell me what you think.
VKTX Long
Need your thought on this pullback. Also need your opinion on how they can do a better job with enrollment in their Trials. Is there something more they can do for recruiting patients like Pay them more ? or is there a fixed amount the FDA allows?
another question I have is how many Bone / muskcoskelatal franchises are out there, and do you know who may be bidding for Vk5211 ? do you think vktx management is holding out as long as they can for best deal ?
I would hold thru this dip...it will bounce back. I think most were worried about the comment CEO made about not going forward with Phase 3 vk5211 without a Partner. But given the fact that the P2 results were excellent I doubt they will have trouble finding a Partner by late summer when they meet with FDA . Also the the CEO mentioned vk2809 was going well but enrollment was hard because of the specific requirements they want in their patients.
The only thing you need to know while holding for another 6 months is they will have a Partner for vk5211 soon and Vk2809 had better P1 report than MDGL lipid drug did and if it has good results in P2 I expect a valuation similar to MDGL....which would put VKTX at 30.00 around late summer or early Fall. Until then is a slow grind up to 12.00 range JMHO
VKTX long